2018 Medicine

Expression of TP53 and IL-1alpha in unicystic ameloblastoma predicts the efficacy of marsupialization treatment.

, , , , ,

Medicine Vol. 97 (6) : e9795 • Feb 2018

In this study, we evaluated the effects of marsupialization in treating unicystic ameloblastoma (UA) and investigated the relationship between TP53 and interleukin 1 alpha (IL-1alpha) expression and the clinical outcome of UA treated with marsupialization.Consecutive patients treated with marsupialization and curettage at Shanghai Ninth People's Hospital were included. According to the unified standard, 48 patients were included in this study. Of these, 20 showed a good response, 10 a partial response, and 18 no response, based on the outcome of the marsupialization procedure. The expression of proteins TP53 and IL-1alpha was detected with immunohistochemistry (IHC). The clinical and pathological characteristics of the patients were analyzed.Analysis of the clinical and pathological characteristics showed that the effects of marsupialization treatment were significantly associated with lesion location (P < .001) and tumor diameter (P = .01). IHC showed that TP53 expression was significantly higher in the good-response group than in the partial- or no-response group (P = .02), and IL-1alpha expression was significantly higher in the good-response group than in the partial- and no-response groups (P = .03).Marsupialization is an effective preliminary procedure for treating UA before curettage and peripheral ostectomy. The expression of the TP53 and IL-1alpha proteins correlates directly with the outcome of UA treated with marsupialization.

No clinical trial protocols linked to this paper

Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.
PICO Elements

No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.

Paper Details
MeSH Terms
+3 more
Associated Data

No associated datasets or code repositories found for this paper.

Related Papers

Related paper suggestions will be available in future updates.